Article
Human immunodeficiency virus type 1 genotypic and pharmacokinetic determinants of the virological response to lopinavir-ritonavir-containing therapy in protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy - 1 Sept 2002
Masquelier Bernard, Breilh Dominique, Neau Didier, Lawson-Ayayi Sylvie, Lavignolle Valérie, Ragnaud Jean-Marie, Dupon Michel, Morlat Philippe, Dabis F, Fleury H
Abstract excerpt
The response to regimens including lopinavir-ritonavir (LPV/r) in patients who have received multiple protease (PR) inhibitors (PI) can be analyzed in terms of human immunodeficiency virus type 1 (HIV-1) genotypic and pharmacokinetic (pK) determinants. We studied these factors and the evolution o...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.